Financials in CAD. Standardized financial statements.
A compact view of how Big Pharma Split Corp. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.45M | $1.85M | $311,764 | $3.93M | $5.36M | $3.08M | $2.43M | $3.23M | $407,111 |
| Revenue Growth? | -21.4% | +493.1% | -92.1% | -26.7% | +74.0% | +26.6% | -24.7% | +693.9% | 0.0% |
| Cost of Revenue? | $313,724 | $315,948 | $308,569 | $419,539 | $355,992 | $277,312 | $238,191 | $274,751 | $0 |
| Gross Profit? | $1.14M | $1.53M | $311,764 | $3.51M | $5.00M | $589,257 | $2.20M | $2.96M | $407,111 |
| Gross Margin? | +78.4% | +82.9% | +100.0% | +89.3% | +93.4% | +19.1% | +90.2% | +91.5% | +100.0% |
| Operating Expenses? | -$3.89M | $540,840 | $451,444 | $565,127 | -$4.46M | $323,834 | $396,467 | $452,017 | $83,890 |
| Operating Income? | $5.03M | $13,408 | -$139,680 | $3.15M | $4.85M | $265,423 | $454,661 | $5.95M | $323,221 |
| EBITDA? | $5.03M | $21,358 | -$137,560 | $3.15M | $4.85M | $265,423 | $454,661 | $2.10M | $323,221 |
| Income Before Tax | $4.40M | -$538,624 | -$645,350 | $2.39M | $4.85M | -$217,388 | $3.14M | $2.78M | $323,221 |
| Income Tax Expense | $0 | $0 | -$505,670 | $0 | $0 | -$217,388 | -$1.34M | $0 | -$3.82M |
| Net Income? | $4.40M | -$538,624 | -$139,680 | $3.15M | $4.85M | $265,423 | $2.58M | $2.78M | $323,221 |
| EPS? | $3.59 | $-0.47 | $-0.53 | $1.58 | $3.27 | $-0.22 | $3.75 | $2.06 | $-0.23 |
| Diluted EPS? | $3.59 | $-0.47 | $-0.53 | $1.58 | $3.27 | $-0.22 | $3.75 | $2.06 | $-0.23 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality